The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

Exclusion Criteria

• •1\. Pregnant or lactating women, or men or women with pregnancy plans within 6 months.
• •2\. Subjects with contagious disease，such as HIV, active HBV and HCV, and syphilis, etc.
• •3\. Subjects with mental or psychological illness who cannot be combined with treatment and efficacy evaluation.
• •4\. Subjects with severe autoimmune disease and long-term use of immunosuppressants.
• •5\. Subjects with active or uncontrollable infections requiring systemic treatment within 14 days prior to enrollment.
• •6\. Subjects with any unstable systemic disease including, but not limited to, active infection (except for local infection), unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III).
• •7\. subjects combined with dysfunction of vital organs such as lung, brain and kidney.
• •8\. subjects that Participated in other similar clinical trials within 6 months.
• •9\. subjects currently receiving treatment for other gene therapy.
• •10\. subjects combined with graft versus host disease (GVHD).
• •11\. Other subjects judged by the researchers to be unsuitable for admission to the study.